News | May 18, 2025
Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
This marks yet another milestone in our series of successful audits over the past year
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs’ proprietary Oral Thin Film technology platform, ThinOral
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
Subscribe To Our Newsletter & Stay Updated
